TLR9 expression in uterine cervical lesions of uyghur women correlate with cervical cancer progression and selective silencing of human papillomavirus 16 E6 and E7 oncoproteins in vitro

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 14, 2014, Pages 5867-5872

  Hao, Yi ^a   Yuan, Jian Ling ^a   Abudula, Abulizi ^b   Hasimu, Axiangu ^a   Kadeer, Nafeisha ^b   Guo, Xia ^b  

^a XINJIANG MEDICAL UNIVERSITY   (China)

^b Xinjiang Key Laboratory of Cardiovascular Disease Research   (China)

Author keywords

Cervical squamous cell carcinoma; Human papillomavirus; siRNA; TRL9; Uyghur women

Indexed keywords

E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; PARAFFIN; PROTEIN E7; REPRESSOR PROTEIN; SMALL INTERFERING RNA; TLR9 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 9;

BIOSYNTHESIS; CHINA; DISEASE COURSE; FEMALE; GENETICS; HISTOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRUS INFECTION; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; UTERINE CERVIX TUMOR; VIROLOGY;

CELL LINE, TUMOR; CHINA; DISEASE PROGRESSION; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PARAFFIN EMBEDDING; REPRESSOR PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TISSUE EMBEDDING; TOLL-LIKE RECEPTOR 9; UTERINE CERVICAL NEOPLASMS;

EID: 84905983911     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.14.5867     Document Type: Article

References (37)

1. Akira S, Takeda K (2004). Toll-like receptor signalling. Nat Rev Immunol, 4, 499-511.
2. Akira S, Uematsu S, Takeuchi O (2006). Pathogen recognition and innate immunity. Cell, 124, 783-01.
3. Cohen J (2005). Pubic health High hopes and dilemmas for a cervical cancer vaccine. Science, 308, 618-21.
4. Clifford GM, Smith JS, Plummer M, et al(2003). Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer, 88, 63-73.
5. Dolganiuc A, Garcia C, Kodys K, et al(2006). Distinct Toll-like receptor expression in monocytes and T cells in chronic HCV infection. World J Gastroenterol, 12, 1198-04.
6. Daud II, Scott ME, Ma Y, et al(2011). Association between toll-like receptor expression and human papillomavirus type 16 persistence. Int J Cancer, 128, 879-86.
7. Ferlay J, Autier P, Boniol M, et al(2007). Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol, 18, 581-92.
8. Frisch M, Biggar RJ, Goedert JJ (2000). Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst, 92, 1500-10.
9. Groskreutz DJ, Monick MM, Powers LS, et al(2006). Respiratory syncytial virus induces TLR3 protein and protein kinase R: leading to increased double-stranded RNA responsiveness in airway epithelial cells. J Immunol, 176, 1733-40.
10. Huang B, Zhao J, Unkeless JC, et al(2008). TLR signaling by tumor and immune cells: a double-edged sword. Oncogene, 27, 218-24.
11. Horsmans Y, Berg T, Desager JP, et al(2005). Isatoribine an agonist of TLR7: reduces plasma virus concentration in chronic hepatitis C infection. Hepatology, 42, 724-31.
12. Hasan UA, Bates E, Takeshita F, et al(2007). TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol, 178, 3186-97.
13. IIvesaro JM, Merrell MA, Swain TM, et al(2007). Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate, 67, 774-81.
14. Krieg AM (2008). Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene, 27, 161-7.
15. Kim WY, Lee JW, Choi JJ, et al(2008). Increased expression of Toll-like receptor 5 during progression of cervical neoplasia. Int J Gynecol Cancer, 18, 300-5.
16. LIU KJ, LIU JW, LI XR, et al(2008). Epidemiology study of risk factors on Uigur and Han cervical cancer in Xinjiang (J). J Xinjiang Med Univ, 31, 1335-8.
17. Lenert PS (2010). Classification, mechanisms of action and therapeutic applications of inhibitory oligonucleotides for toll-like receptors (TLR) 7 and 9. Mediators Inflamm, 2010, 986596.
18. Lee JW, Choi JJ, Seo ES, et al(2007). Increased toll-like receptor 9 expression in cervical neoplasia. Mol Carcinog, 46, 941-7.
19. Matijevic T, Pavelic J (2010). Toll-like receptors: cost or benefit for cancer. Curr Pharm, 16, 1081-90.
20. Mishra A, Bharti AC, Varghese P, et al(2006). Differential expression and activation of NF-kappaB family proteins during oral carcinogenesis: role of high risk human papillomavirus infection. Int J Cancer, 119, 2840-50.
21. Mukherjee S, Siddiqui MA, Dayal S, et al(2014). Epigallocatechin-3-gallate suppresses proinflammatory cytokines and chemokines induced by Toll-like receptor 9 agonists in prostate cancer cells. J Inflamm Res, 17, 89-101.
22. Nees M, Geoghegan JM, Hyman T, et al(2001). Papillomavirus type 16 oncogenes down-regulate expression of interferon-responsive genes and up-regulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J Virol, 75, 4283-96.
23. Ostor AG (1993). Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol, 12, 186-92.
24. Ren T, Wen ZK, Liu ZM, et al(2007). Functional expression of TLR9 is associated to the metastatic potential of human lung cancer cell: functional active role of TLR9 on tumor metastasis. Cancer Biol Ther, 6, 1704-9.
25. Stanley MA, Pett MR, Coleman N (2007). HPV: from infection to cancer. Biochem Soc Trans, 35, 1456-60.
26. Sato Y, Goto Y, Narita N, et al(2009). Cancer cells expressing toll-like receptors and the tumor microenvironment. Cancer Microenviron, 2, 205-14.
27. Suzuke L, Peng YH, Zhou K, et al(2006). The analysis of pathogenetic tendency of cervical cancer in various ethnic women in Xinjiang. J Xinjiang Med Univ, 29, 569-71.
28. Tezcan S, Ozgur D, Ulger M, et al(2014). Human papillomavirus genotype distribution and E6/ E7 oncogene expression in Turkish women with cervical cytological findings. Asian Pac J Cancer Prev, 15, 3997-4003.
29. Tommasino M (2001). Early genes of human papillomaviruses: In Encyclopedic Reference of Cancer. Springer-Verlag, Heidelberg, 262-272.
30. Takeshita F, Gursel I, Ishii KJ, et al(2004). Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. Semin Immunol, 16, 17-22.
31. Takeshita F, Suzuki K, Sasaki S, et al(2004). Transcriptional regulation of the human TLR9 gene. J Immunol, 173, 2552-61.
32. Wu XM, Liu X, Jiao QF, et al(2014). Cytotoxic T lymphocytes elicited by dendritic cell-targeted delivery of human papillomavirus type-16 E6/E7 fusion gene exert lethal effects on CaSki cells. Asian Pac J Cancer Prev, 15, 2447-51.
33. Wang D, Xiao PL, Duan HX, et al(2012). Peptidoglycans Promotes Human Leukemic THP-1 Cell Apoptosis and Differentiation. Asian Pacific J Cancer Prev, 13, 6409-13.
34. Yang BH, Bray FI, Parkin DM, et al(2004). Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Int J Cancer, 109, 418-24.
35. Wang D, Xiao PL, Duan HX, et al(2012). Lack of association of three common polymorphisms in Toll-like receptors (TLRs), TLR2+597T>C, +1350C>T and Arg753Gln with cancer risk: a meta-analysis. Asian Pac J Cancer Prev, 14, 5871-76.
36. Zhang GQ, LIU KJ, Lai XJ, et al(2003). Distribution of malignant tumor patients in hospital from 1989 to 2002 in the Affiliated Tumor Hospital of Xinjiang Medical University. J Xinjiang Med Univ, 26, 393-5.
37. Zhang SQ, Yakup K, Abliz G, et al(2009). The study of the relationships between HPV multiple infection and cervical cancer of Uygur Women in Xinjiang. J Xinjiang Med Univ, 32, 525-8.